TAK - TAKEDA PHARMACEUTICAL CO LTD
18.22
0.140 0.768%
Share volume: 2,765,644
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$18.08
0.14
0.01%
View ratios
| Fiscal Date | 06-30-2023 | 09-30-2023 | |
|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | |
| Report Date | 07-27-2023 | 10-30-2023 | |
| Total revenue | 7.316 B | 6.983 B | |
| Cost of revenue | 2.219 B | 2.300 B | |
| Gross profit | 5.097 B | 4.683 B | |
| -8.12% | |||
| Operating expenses | 2.839 B | 2.925 B | |
| Selling general and admin | 1.715 B | 1.693 B | |
| Research and development | 1.125 B | 1.231 B | |
| Total expenses | 5.956 B | 6.820 B | |
| 14.51% | |||
| Operating income | 1.360 B | 163.294 M | |
| Ebit | 1.360 B | 163.294 M | |
| Pretax income | 933.154 M | -642.544 M | |
| -168.86% | |||
| Income tax | 315.308 M | -321.399 M | |
| Net income basic | 617.770 M | -321.540 M | |
| -152.05% | |||
| Net income | 617.770 M | -321.540 M | |
| -152.05% |